- Per the August 2026 labels for Zepbound® (tirzepatide) and Mounjaro® (tirzepatide), the tirzepatide dosage chart has six weekly doses: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each 2.5 mg step needs at least 4 weeks on the current dose.
- Zepbound® maintenance doses are 5, 10 or 15 mg for weight, or 10 or 15 mg for sleep apnea, per its label. Mounjaro® steps up only if more blood sugar control is needed. Both labels cap adults at 15 mg.
- In the SURMOUNT-1 trial of 2,539 adults, people on 5, 10 and 15 mg lost 15.0%, 19.5% and 20.9% of body weight over 72 weeks. People on placebo lost 3.1%, per the Zepbound® label.
- Units measure liquid on a U-100 syringe, not the amount of drug. Every Zepbound® or Mounjaro® single-dose vial dose is 0.5 mL per their labels, which is 50 units. For other vials, units depend on the label's mg/mL.
Starting a weekly shot comes with practical questions: which dose comes next, when you can move up, and what to do after a missed week. Our tirzepatide dosage chart answers them from the Zepbound® and Mounjaro® labels, both revised in August 2026.
Read on for the week-by-week schedule, results by dose, and doses in units and mL.
Tirzepatide dosage chart: what are all the doses?
The tirzepatide dosage chart has six once-weekly doses, 2.5, 5, 7.5, 10, 12.5 and 15 mg, according to the Zepbound® and Mounjaro® labels revised in August 2026. Both brands start at 2.5 mg. Each step adds 2.5 mg after at least 4 weeks on the current dose; on Mounjaro®, only if more blood sugar control is needed.
Tirzepatide dosage chart: Zepbound® and Mounjaro® doses by week
| Dose (once weekly) | Earliest weeks on the label path | Zepbound® role | Mounjaro® role |
|---|---|---|---|
| 2.5 mg | Weeks 1 to 4 | Starting dose only; not approved as a maintenance dose | Starting dose; step up only if more blood sugar control is needed |
| 5 mg | Weeks 5 to 8 | Step, or maintenance dose for weight (not for sleep apnea) | Step or continuing dose |
| 7.5 mg | Weeks 9 to 12 | Step dose (not a labeled maintenance dose) | Step or continuing dose |
| 10 mg | Weeks 13 to 16 | Step, or maintenance dose for weight or sleep apnea | Step or continuing dose; highest dose for children 10 and older |
| 12.5 mg | Weeks 17 to 20 | Step dose (not a labeled maintenance dose) | Step or continuing dose (adults only) |
| 15 mg | Week 21 onward | Maintenance dose for weight or sleep apnea; maximum dose | Maximum dose for adults |
Source: Zepbound® and Mounjaro® Prescribing Information, revised August 2026, section 2. Earliest weeks assume each step happens after exactly 4 weeks; the prescriber may keep you on a dose longer. The Mounjaro® label names no maintenance doses.
Important safety information
Before you start or change a dose, read the Zepbound® Prescribing Information and Mounjaro® Prescribing Information, both revised in August 2026, including the boxed warning.
Tirzepatide is taken once a week, on the same day each week, according to the Zepbound® and Mounjaro® labels. Time of day and meals do not matter for a tirzepatide shot: the labels say to inject it at any time of day, with or without meals.
You inject it under the skin of the stomach area or thigh, or someone else can use the back of your upper arm. Rotate the injection site each week.
The Zepbound® label lists 5, 10 or 15 mg once a week as the maintenance doses (the doses you stay on) for weight. Mounjaro® is approved for type 2 diabetes, not weight loss.
Tirzepatide is a GIP and GLP-1 receptor agonist (a weekly shot that acts on two gut hormone receptors). For how the medicine works in the body, see how tirzepatide works for weight loss and diabetes.
What is the tirzepatide titration schedule, week by week?
The tirzepatide titration schedule (how the dose steps up) starts at 2.5 mg once a week for 4 weeks, per the Zepbound® label. Each later step adds 2.5 mg after at least 4 weeks on the current dose.
The Zepbound® dose schedule moves everyone from 2.5 mg to 5 mg after 4 weeks. After that, the Zepbound® label says the dose "may be increased" in 2.5 mg steps.
Mounjaro® uses the same 2.5 mg steps, after at least 4 weeks on the current dose, but only "if additional glycemic control is needed" (more blood sugar control).
Fastest step-up path allowed by the labels
- Weeks 1 to 4: 2.5 mg once a week.
- Weeks 5 to 8: 5 mg once a week.
- Weeks 9 to 12: 7.5 mg once a week.
- Weeks 13 to 16: 10 mg once a week.
- Weeks 17 to 20: 12.5 mg once a week.
- Week 21 onward: 15 mg once a week.
Reaching the highest tirzepatide dose, 15 mg, takes at least 20 weeks: under the Zepbound® and Mounjaro® labels, the earliest week to start 15 mg is week 21. The SURMOUNT-1 trial of 2,539 adults also used a dose-escalation period of up to 20 weeks.
The Zepbound® label says to step up slowly "to reduce the risk of gastrointestinal adverse reactions," meaning stomach and bowel side effects.
You do not have to keep going up to 15 mg: the Zepbound® label says to consider treatment response and tolerability when choosing the maintenance dose. Mounjaro® steps depend on blood sugar control, and your prescriber decides each step.
Can you increase your tirzepatide dose after 2 weeks?
No, neither tirzepatide label allows a dose increase after 2 weeks: Zepbound® and Mounjaro® both require at least 4 weeks on the current dose first.
Tirzepatide levels in the body reach a steady state (a stable level) after about 4 weeks of weekly doses, according to the Zepbound® label.
Zepbound® doses vs. Mounjaro® doses: what is the difference?
Zepbound® and Mounjaro® doses use the same six strengths and 2.5 mg steps, per their August 2026 labels, but the two brands are approved for different uses. Zepbound® (tirzepatide) treats adults with obesity, or overweight plus a weight-related condition, along with a reduced-calorie diet and more physical activity.
Zepbound® also treats moderate to severe obstructive sleep apnea (OSA, breathing that stops and starts during sleep) in adults with obesity.
Mounjaro® (tirzepatide) is used with diet and exercise to improve blood sugar in adults and children 10 and older with type 2 diabetes. It also lowers the risk of major heart and blood vessel events in adults with type 2 diabetes at high risk.
Zepbound® doses vs. Mounjaro® doses by approved use (Mounjaro® dosage chart included)
| Brand and approved use | Starting dose | Maintenance doses on the label | Maximum weekly dose |
|---|---|---|---|
| Zepbound®: weight reduction and long-term maintenance (adults with obesity, or overweight plus a weight-related condition) | 2.5 mg for 4 weeks (start only) | 5, 10 or 15 mg | 15 mg |
| Zepbound®: moderate to severe obstructive sleep apnea (adults with obesity) | 2.5 mg for 4 weeks (start only) | 10 or 15 mg | 15 mg |
| Zepbound®: children | Not established | Does not apply | Does not apply |
| Mounjaro®: type 2 diabetes, adults | 2.5 mg | Not named; 2.5 mg steps only if more blood sugar control is needed | 15 mg |
| Mounjaro®: type 2 diabetes, children 10 and older | 2.5 mg | Not named | 10 mg |
| Mounjaro®: lowering major heart and blood vessel events in adults with type 2 diabetes at high risk | 2.5 mg | Not named | 15 mg |
| Mounjaro®: weight loss | Not an FDA-approved use (off-label) | Does not apply | Does not apply |
Sources: Zepbound® Prescribing Information (revised 08/2026; DailyMed version of August 28, 2026) and Mounjaro® Prescribing Information (revised 08/2026; DailyMed version of August 27, 2026), sections 1 and 2. Zepbound® is approved for use with a reduced-calorie diet and increased physical activity; Mounjaro®'s diabetes use is with diet and exercise.
The Zepbound® dose for obstructive sleep apnea is 10 or 15 mg once a week, according to its label. The 5 mg dose is not a sleep apnea maintenance dose. In the SURMOUNT-OSA trials, people on Zepbound® took the highest dose they tolerated, 10 or 15 mg.
Mounjaro® is FDA-approved for type 2 diabetes, not weight loss, so using it for weight loss is off-label. FDA approved tirzepatide for weight as a separate brand, Zepbound®, on November 8, 2023, per FDA approval records. Read more in Zepbound® vs. Mounjaro®: same drug, different uses.
A prescriber can switch you between Zepbound® and Mounjaro® (both tirzepatide), but neither label gives switching instructions, and Mounjaro® for weight loss is off-label. The Zepbound® label advises against using it with other tirzepatide products or with any GLP-1 medicine.
Good to know
The Mounjaro® label was updated on August 27, 2026, and no longer says to move from 2.5 mg to 5 mg after 4 weeks. Now every 2.5 mg step, including the first, comes after at least 4 weeks and only "if additional glycemic control is needed." Older copies of the label, and some websites, still show the earlier schedule.
[COMMERCIAL MODULE SLOT: "See if you qualify for Zepbound®" (theme-managed; informational copy only; no prices; no provider names; no link in body copy)]
What are the starting, maintenance and maximum doses of tirzepatide?
Tirzepatide dosing starts at 2.5 mg a week and tops out at 15 mg for adults (10 mg for children on Mounjaro®), per the Zepbound® and Mounjaro® labels. Zepbound® maintenance doses are 5, 10 or 15 mg for weight and 10 or 15 mg for sleep apnea; the Mounjaro® label names no maintenance dose.
What is the starting dose of tirzepatide?
The starting dose of tirzepatide is 2.5 mg once a week, according to the Zepbound® and Mounjaro® labels; the Zepbound® label sets it for 4 weeks. Both labels start low and step up slowly "to reduce the risk of gastrointestinal adverse reactions" (stomach and bowel side effects).
The Zepbound® label adds that 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage." The Mounjaro® label starts at 2.5 mg and steps up only if more blood sugar control is needed. The SURMOUNT-1 trial tested 5, 10 and 15 mg, not 2.5 mg, as treatment doses.
Yes, 2.5 mg is the lowest tirzepatide dose on the Zepbound® and Mounjaro® labels. Microdosing tirzepatide means taking less than the 2.5 mg starting dose, and no FDA-approved tirzepatide label includes such a dose.
Early research tested a lower dose: a 2018 phase 2 trial in The Lancet gave 1 mg a week to some adults with type 2 diabetes. The trial of 318 adults ran 26 weeks, and its main goal was blood sugar control, not testing low doses for weight loss. Learn more about microdosing tirzepatide and what the evidence says.
What is the maximum dose of tirzepatide?
The maximum dose of tirzepatide is 15 mg once a week for adults, on both the Zepbound® and Mounjaro® labels. The Mounjaro® maximum for children 10 and older is 10 mg. Neither label lists a tirzepatide dose above 15 mg a week.
Tirzepatide maximum and maintenance dose facts
| Fact | Value | Source |
|---|---|---|
| Highest labeled dose, adults | 15 mg once weekly (Zepbound® and Mounjaro®) | Labels, section 2 |
| Highest labeled dose, children 10 and older | 10 mg once weekly (Mounjaro® only; Zepbound® is not approved for children) | Mounjaro® section 2.1; Zepbound® section 8.4 |
| Doses above 15 mg | Not on the Zepbound® or Mounjaro® label | Labels, section 2 |
| Earliest week to reach 15 mg | Week 21, after 20 weeks on lower doses | Computed from section 2.1 |
| Maintenance doses, Zepbound® | 5, 10 or 15 mg (weight); 10 or 15 mg (sleep apnea) | Zepbound® section 2.2 |
| Maintenance doses, Mounjaro® | Not named | Mounjaro® section 2.1 |
| Share whose highest tolerated dose was 15 mg | 86% of people on Zepbound® in SURMOUNT-3 (579 adults, stepped up to 10 or 15 mg as tolerated) | Zepbound® section 14.1 |
| If a maintenance dose is not tolerated | The Zepbound® label says to consider a lower maintenance dose | Zepbound® section 2.1 |
Sources: Zepbound® and Mounjaro® Prescribing Information, revised August 2026.
What is the maintenance dose of tirzepatide?
The maintenance dose of Zepbound® is 5, 10 or 15 mg once a week for weight, or 10 or 15 mg for sleep apnea, according to its label. The Mounjaro® label does not name maintenance doses. The prescriber picks the dose based on how well it works and how well you tolerate it.
Neither tirzepatide label names a usual maintenance dose. In the SURMOUNT-3 trial of 579 adults with obesity or overweight, people on Zepbound® were stepped up to the highest dose they tolerated, 10 or 15 mg. By the end of 72 weeks, 86% of them had 15 mg as their highest tolerated dose, per the Zepbound® label.
In the SURMOUNT-MAINTAIN trial (The Lancet, 2026), stepping down to tirzepatide 5 mg kept more weight off than switching to placebo. Adults with obesity or overweight first took tirzepatide at their highest tolerated dose, 10 or 15 mg, for 60 weeks.
Then 378 were randomly assigned to stay on that dose, drop to 5 mg, or switch to placebo for 52 weeks. At week 112, weight was 21.9% below the trial-start weight on the full dose, 16.6% on 5 mg and 9.9% on placebo. For what happens after goal weight, read what happens after stopping Zepbound® or Wegovy® (semaglutide).
How much weight loss does each tirzepatide dose bring?
In the SURMOUNT-1 trial of 2,539 adults, tirzepatide 5, 10 and 15 mg lowered body weight by 15.0%, 19.5% and 20.9% over 72 weeks, vs 3.1% on placebo. Those are the results printed in the Zepbound® label revised in August 2026, and they come from the brand-name medicine.
Tirzepatide results by dose in FDA label trials
| Trial (who, how long) | Result | 5 mg | 10 mg | 15 mg | Comparison group |
|---|---|---|---|---|---|
| SURMOUNT-1: 2,539 adults with obesity or overweight, without diabetes; 72 weeks | Average body weight change | -15.0% | -19.5% | -20.9% | Placebo: -3.1% |
| SURMOUNT-1 | Share who lost 20% or more of body weight | 30.0% | 50.1% | 56.7% | Placebo: 3.1% |
| SURMOUNT-2: 938 adults with type 2 diabetes and overweight or obesity; 72 weeks | Average body weight change | Not tested | -12.8% | -14.7% | Placebo: -3.2% |
| SURPASS-2: 1,879 adults with type 2 diabetes on metformin; 40 weeks | A1C change (percentage points) | -2.0 | -2.2 | -2.3 | Semaglutide 1 mg: -1.9 |
| SURPASS-2 | Body weight change | -7.6 kg | -9.3 kg | -11.2 kg | Semaglutide 1 mg: -5.7 kg |
Sources: Zepbound® Prescribing Information (section 14.1, Table 2) and Mounjaro® Prescribing Information (section 14.3, Table 5), revised August 2026. People were randomly assigned to one dose and stepped up to it; results are averages for everyone assigned, including people who stopped.
Tirzepatide 5 mg led to weight loss in SURMOUNT-1, the main Zepbound® weight trial. Over 72 weeks, 85.1% of people on 5 mg lost at least 5% of their weight, vs 34.5% on placebo.
Higher tirzepatide doses brought more weight loss in SURMOUNT-1, but the extra benefit shrank at the top. By our calculation from the Zepbound® label, the 10 mg group lost 4.5 percentage points more than the 5 mg group. The 15 mg group lost 1.4 points more than the 10 mg group.
In the SURPASS-2 trial of 1,879 adults with type 2 diabetes, Mounjaro® lowered A1C (average blood sugar over the past few months) at every dose over 40 weeks. A1C fell by 2.0, 2.2 and 2.3 points on 5, 10 and 15 mg, vs 1.9 points on semaglutide 1 mg. Participants started at an average A1C of 8.3%.
The SURMOUNT-OSA trials enrolled 469 adults with obesity and sleep apnea for 52 weeks. Half took Zepbound® at the highest dose they tolerated, 10 or 15 mg, and half took placebo.
In SURMOUNT-OSA, Zepbound® lowered the apnea-hypopnea index (AHI) by 25.3 events per hour at 52 weeks in people not using a PAP breathing machine, vs 5.3 on placebo. AHI counts breathing pauses per hour of sleep. In people using PAP, Zepbound® lowered AHI by 29.3, vs 5.5 on placebo.
Some websites show higher SURMOUNT-1 numbers, such as 22.5% weight loss at 15 mg. That figure, posted on ClinicalTrials.gov, is the trial's efficacy estimand: it counts only people who kept taking the medicine.
Do tirzepatide side effects get worse at higher doses?
Most tirzepatide nausea, vomiting and diarrhea happen while the dose is being raised and ease over time, per the Zepbound® and Mounjaro® labels. Some side effects rise with the dose: in Zepbound® label trials, vomiting affected 8%, 11% and 13% of people on 5, 10 and 15 mg, vs 2% on placebo.
In the same Zepbound® trials, nausea did not keep rising with the dose (25%, 29% and 28%). Constipation fell as the dose went up (17%, 14% and 11%).
Zepbound® side effects by dose in label trials
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Any stomach or bowel side effect | 30% | 56% | 56% | 56% |
| Severe stomach or bowel side effect | 1% | 1.7% | 2.5% | 3.1% |
| Stopped because of a stomach or bowel side effect | 0.5% | 1.9% | 3.3% | 4.3% |
Source: Zepbound® Prescribing Information, revised August 2026 (sections 5.2 and 6.1, Table 1). Pooled SURMOUNT-1 and SURMOUNT-2 data, up to 72 weeks: 958 people on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg. Each group stepped up through lower doses first.
In label trials, 4.8%, 6.3% and 6.7% of people on Zepbound® 5, 10 and 15 mg stopped because of side effects, vs 3.4% on placebo. Most who stopped did so in the first few months, because of stomach side effects.
Mounjaro® stomach side effects also rise with the dose, per its label's pool of two 40-week trials in adults with type 2 diabetes. Stomach or bowel side effects affected 37.1%, 39.6% and 43.6% of people on Mounjaro® 5, 10 and 15 mg, vs 20.4% on placebo.
Tirzepatide side effects like vomiting and diarrhea can cause dehydration, which can harm the kidneys. The Zepbound® label calls for kidney checks in people with these side effects, especially when starting or raising a dose.
The Zepbound® Medication Guide says to drink fluids to lower the chance of dehydration. Tell your provider right away about nausea, vomiting or diarrhea that does not go away.
What helps side effects after a tirzepatide dose increase?
Smaller meals and fewer fatty or high-fiber foods can ease stomach side effects after a tirzepatide dose increase, per a 2025 joint advisory. Your prescriber can also suggest anti-nausea medicine, more time on a dose, or a lower maintenance dose.
Problem: nausea, vomiting, diarrhea or stomach pain in the days after a step-up to a higher tirzepatide dose.
Possible cause: tirzepatide slows how fast the stomach empties (delayed gastric emptying). The Zepbound® label says this delay is largest after the first dose and gets smaller over time.
Fix: these steps come from the Zepbound® label and Medication Guide, a 2025 joint advisory and a 2022 expert consensus.
- Smaller meals: eat smaller, more frequent meals and skip fatty or high-fiber foods in the first days. A 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society suggests this.
- Fluids: drink enough fluids to avoid dehydration, as the Zepbound® Medication Guide advises.
- Anti-nausea medicine: ask your prescriber about an anti-nausea medicine during dose increases, an option the 2025 advisory describes.
- More time on a dose: the 2025 advisory says some people may benefit from a slower titration schedule. A 2022 multidisciplinary expert consensus on GLP-1 medicines suggests 2 to 4 more weeks on the previous dose. It covers the drug class and does not name tirzepatide.
Yes, you can stay on a lower tirzepatide dose if side effects are bad: the Zepbound® label says to consider a lower maintenance dose, and your prescriber decides. Neither tirzepatide label sets a rule to delay a dose increase; slower schedules come from expert advice.
[EDITOR QUOTE SLOT: PharmD judgment on holding a tirzepatide dose when side effects persist after a step-up. Real, named and logged quote only.]
Can tirzepatide cause low blood sugar?
Tirzepatide can cause low blood sugar (hypoglycemia) mainly when taken with insulin or a sulfonylurea (an older type of diabetes pill). The Zepbound® and Mounjaro® labels say the prescriber may lower the dose of those medicines.
In the 72-week SURMOUNT-2 trial of 938 adults with type 2 diabetes, 4.2% on Zepbound® had blood sugar below 54 mg/dL, vs 1.3% on placebo. Among people on Zepbound® in SURMOUNT-2, 10.3% of those also taking a sulfonylurea had blood sugar below 54 mg/dL, vs 2.1% of those not taking one.
In one adult trial of up to 104 weeks, blood sugar fell below 54 mg/dL in 13.8%, 9.9% and 12.8% on Mounjaro® 5, 10 and 15 mg plus a sulfonylurea.
The Zepbound® Medication Guide lists the signs of low blood sugar. They include dizziness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech and shakiness. Others are a fast heartbeat, anxiety or mood changes, hunger, weakness and feeling jittery.
What does the tirzepatide boxed warning mean?
Tirzepatide has a boxed warning, the FDA's strongest label warning, because it caused thyroid C-cell tumors (growths in certain thyroid cells) in rats; whether it does in people is unknown. In rats, the tumors were linked to higher doses and longer use.
People with a personal or family history of medullary thyroid carcinoma (MTC, a rare thyroid cancer) should not take tirzepatide. The same goes for MEN 2 (an inherited condition that causes gland tumors).
While taking tirzepatide, tell your provider about a lump or swelling in the neck, trouble swallowing, shortness of breath, or hoarseness that will not go away.
Related reading • Zepbound® side effects: common and serious: What the label says about every Zepbound® side effect, not only stomach ones. • How long do Wegovy® and Zepbound® take to work?: What to expect week by week once you are on a steady dose. • Zepbound® vs. Mounjaro®: same drug, different uses: Why one tirzepatide brand treats weight and the other treats diabetes. • What happens after stopping Zepbound® or Wegovy®?: What trials show about stopping or lowering the dose after goal weight.
What should you do if you miss a tirzepatide dose?
Take a missed tirzepatide dose within 4 days (96 hours); after 4 days, skip it and take the next dose on your regular day, per the Zepbound® and Mounjaro® labels.
Missed dose steps from the labels
- Count the days since your usual injection day.
- If 4 days (96 hours) or less have passed, take the missed dose now, then go back to your weekly schedule.
- If more than 4 days have passed, skip the missed dose and take the next one on your regular day.
- Never take 2 doses within 3 days (72 hours) of each other.
Yes, you can change your tirzepatide injection day, per the Zepbound® and Mounjaro® labels, as long as at least 3 days (72 hours) pass between the two doses.
If you take too much tirzepatide, such as two doses by mistake, call your provider or the Poison Help line at 1-800-222-1222 right away. You can also go to the nearest ER, per the Zepbound® Medication Guide.
Tirzepatide stays in the body a long time: its half-life (the time for the level to drop by half) is about 5 days, per the Zepbound® label. Because of this, the label says a period of watching and treatment may be needed after too large a dose.
Neither the Zepbound® nor the Mounjaro® label says which dose to restart after you miss several weeks, so ask your prescriber before your next injection.
Can you split a tirzepatide dose or take it twice a week?
No, the Zepbound® and Mounjaro® labels describe once-weekly dosing only, with no split-dose or twice-weekly schedule.
Single-dose pens and vials hold one full dose each, and the KwikPen gives a set dose with each of its 4 injections. Ask your prescriber before changing how or when you take a dose.
What forms do Zepbound® and Mounjaro® doses come in?
Zepbound® and Mounjaro® come as single-dose pens, single-dose vials, multi-dose vials and the 4-dose KwikPen, each in the same six strengths, per their August 2026 labels. FDA approved the multi-dose vial on January 7, 2026, and the KwikPen on January 20, 2026, for both brands, per FDA approval records.
Zepbound® and Mounjaro® forms and strengths
| Form | Strengths (dose per injection) | Liquid per dose | Doses per pen or vial | Good to know |
|---|---|---|---|---|
| Single-dose pen | 2.5, 5, 7.5, 10, 12.5 or 15 mg | 0.5 mL | 1 | Gives the full dose in one injection |
| Single-dose vial | 2.5, 5, 7.5, 10, 12.5 or 15 mg | 0.5 mL | 1 | Needs a syringe that can measure the dose; use a new syringe and needle each time |
| Multi-dose vial | 2.5 to 15 mg per dose (10 to 60 mg per 2.4 mL; 4.17 to 25 mg/mL) | 0.6 mL | 4 | Throw away after 4 weekly doses or 30 days after first use, even if medicine is left |
| KwikPen | 2.5 to 15 mg per dose (10 to 60 mg per 2.4 mL; 4.17 to 25 mg/mL) | 0.6 mL, set by the pen | 4 | Single-patient use; never share, even with a new needle |
Sources: Zepbound® and Mounjaro® Prescribing Information, revised August 2026 (sections 3 and 16); FDA approval records. Strengths and volumes are the same for both brands.
The KwikPen does not change tirzepatide dosing: it holds 4 weekly doses of one strength and gives a set dose each time. The labels do not recommend the KwikPen for people with vision problems to use on their own. Your provider should train you on the device you use.
There is no tirzepatide pill: every FDA-approved form is an injection under the skin, as of October 2026.
Tirzepatide dosage in units and mL: how do you convert mg to units?
Units measure liquid volume on a U-100 insulin syringe, not the amount of tirzepatide, so the units for a dose depend on the medicine's strength in mg per mL. On a U-100 syringe, 100 units equal 1 mL, according to MedlinePlus.
How to convert a tirzepatide dose
- mL to inject = dose in mg divided by concentration in mg/mL.
- Units on a U-100 syringe = mL times 100.
- Reverse: mg = units divided by 100, times the concentration in mg/mL.
Use the mg/mL on your own label; your prescriber's and pharmacy's instructions come first.
The charts on this page apply only to U-100 syringes. Pens, including the KwikPen, are not measured in units.
How many units is a Zepbound® or Mounjaro® vial dose?
Every Zepbound® or Mounjaro® single-dose vial dose is 0.5 mL, which is 50 units on a U-100 syringe, at every strength from 2.5 to 15 mg, per the labels. Every multi-dose vial dose is 0.6 mL, or 60 units, because the vial strength changes with the dose instead of the volume.
Tirzepatide vial doses in mL and units (Zepbound® and Mounjaro® labels)
| Dose | Single-dose vial (strength) | Single-dose: liquid to draw | Single-dose: U-100 units | Multi-dose vial (strength) | Multi-dose: liquid to draw | Multi-dose: U-100 units |
|---|---|---|---|---|---|---|
| 2.5 mg | 2.5 mg/0.5 mL | 0.5 mL | 50 | 10 mg/2.4 mL | 0.6 mL | 60 |
| 5 mg | 5 mg/0.5 mL | 0.5 mL | 50 | 20 mg/2.4 mL | 0.6 mL | 60 |
| 7.5 mg | 7.5 mg/0.5 mL | 0.5 mL | 50 | 30 mg/2.4 mL | 0.6 mL | 60 |
| 10 mg | 10 mg/0.5 mL | 0.5 mL | 50 | 40 mg/2.4 mL | 0.6 mL | 60 |
| 12.5 mg | 12.5 mg/0.5 mL | 0.5 mL | 50 | 50 mg/2.4 mL | 0.6 mL | 60 |
| 15 mg | 15 mg/0.5 mL | 0.5 mL | 50 | 60 mg/2.4 mL | 0.6 mL | 60 |
Sources: Zepbound® and Mounjaro® Prescribing Information, revised August 2026, sections 3 and 16. Units are arithmetic for a U-100 syringe (100 units = 1 mL); the labels give mL only.
Good to know
The Zepbound® and Mounjaro® labels never give a tirzepatide dose in units. They give each dose in mg and mL and call for a 1 mL syringe that can measure a 0.5 mL or 0.6 mL dose. The units figures here are arithmetic for a U-100 syringe.
How many units is each dose of compounded tirzepatide?
The units for a compounded tirzepatide dose depend on its concentration: 2.5 mg is 50 units at 5 mg/mL but 25 units at 10 mg/mL on a U-100 syringe.
Compounded tirzepatide is not FDA-approved and is not a generic version of Zepbound® or Mounjaro®. The FDA does not review compounded drugs for safety, effectiveness or quality, and the trial results on this page come from Zepbound® and Mounjaro®.
FDA declared the tirzepatide shortage resolved on October 2, 2024, and confirmed it on December 19, 2024. As of FDA's April 1, 2026 update, tirzepatide is not on FDA's drug shortage list. Read more about compounded tirzepatide and how it differs from Zepbound®.
Compounded tirzepatide is not dosed by an FDA label the way Zepbound® is: it has no FDA-approved dose or schedule, so the prescriber sets the dose. The pharmacy sets the concentration, which sets the units.
Units for the same tirzepatide dose differ between pharmacies because each pharmacy's concentration (mg/mL) can differ.
Use the mg/mL printed on your own prescription label, and if your prescriber's or pharmacy's instructions differ from any chart here, follow their instructions.
Tirzepatide units conversion chart by concentration (U-100 syringe)
| Concentration | 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg |
|---|---|---|---|---|---|---|
| 5 mg/mL | 0.500 mL = 50.0 units | 1.000 mL = 100.0 units | 1.500 mL = 150.0 units (over 1 mL: does not fit one 1 mL syringe) | 2.000 mL = 200.0 units (over 1 mL: does not fit one 1 mL syringe) | 2.500 mL = 250.0 units (over 1 mL: does not fit one 1 mL syringe) | 3.000 mL = 300.0 units (over 1 mL: does not fit one 1 mL syringe) |
| 10 mg/mL | 0.250 mL = 25.0 units | 0.500 mL = 50.0 units | 0.750 mL = 75.0 units | 1.000 mL = 100.0 units | 1.250 mL = 125.0 units (over 1 mL: does not fit one 1 mL syringe) | 1.500 mL = 150.0 units (over 1 mL: does not fit one 1 mL syringe) |
| 12.5 mg/mL | 0.200 mL = 20.0 units | 0.400 mL = 40.0 units | 0.600 mL = 60.0 units | 0.800 mL = 80.0 units | 1.000 mL = 100.0 units | 1.200 mL = 120.0 units (over 1 mL: does not fit one 1 mL syringe) |
| 15 mg/mL | 0.167 mL = 16.7 units | 0.333 mL = 33.3 units | 0.500 mL = 50.0 units | 0.667 mL = 66.7 units | 0.833 mL = 83.3 units | 1.000 mL = 100.0 units |
| 20 mg/mL | 0.125 mL = 12.5 units | 0.250 mL = 25.0 units | 0.375 mL = 37.5 units | 0.500 mL = 50.0 units | 0.625 mL = 62.5 units | 0.750 mL = 75.0 units |
| 25 mg/mL | 0.100 mL = 10.0 units | 0.200 mL = 20.0 units | 0.300 mL = 30.0 units | 0.400 mL = 40.0 units | 0.500 mL = 50.0 units | 0.600 mL = 60.0 units |
| 30 mg/mL | 0.083 mL = 8.3 units | 0.167 mL = 16.7 units | 0.250 mL = 25.0 units | 0.333 mL = 33.3 units | 0.417 mL = 41.7 units | 0.500 mL = 50.0 units |
Arithmetic only: mL = dose divided by concentration; units = mL times 100. The concentrations are examples, not products. Cells marked over 1 mL do not fit in one 1 mL syringe. Your prescriber sets the dose. Some cells, such as 16.7 units, fall between syringe markings; ask your pharmacist how to measure them.
For compounded tirzepatide in multi-dose vials, FDA advises throwing the vial away 28 days after first use, even if medicine is left. FDA also advises a new sterile needle and syringe for each dose.
How many mg is 20 units or 40 units of tirzepatide?
Twenty units of tirzepatide on a U-100 syringe is 2 mg at 10 mg/mL but 1 mg at 5 mg/mL, because units measure liquid, not drug. Forty units is 4 mg at 10 mg/mL or 2 mg at 5 mg/mL. To turn units into mg, divide the units by 100, then multiply by the mg/mL on the label.
- 25 units: 2.5 mg at 10 mg/mL, or 1.25 mg at 5 mg/mL.
- 30 units: 3.0 mg at 10 mg/mL, or 1.5 mg at 5 mg/mL.
- 50 units: 0.5 mL, which is one full Zepbound® or Mounjaro® single-dose vial dose at any strength.
Check the mg/mL on your label before you read any units number.
What dosing errors has the FDA reported with compounded GLP-1 shots?
FDA's dosing-error alert for compounded GLP-1 shots, dated July 26, 2024, covered compounded semaglutide: some patients took 5 to 20 times their intended dose. For compounded tirzepatide, FDA has received adverse event reports that may be related to doses beyond the FDA-approved label.
FDA said some semaglutide patients got syringes much larger than their dose, and confusion between milliliters, milligrams and units may have contributed to the errors. The same mix-up is possible with tirzepatide, because the same number of units holds a different mg dose at each concentration.
In a March 2024 safety alert, the Institute for Safe Medication Practices described a patient told to inject 5 units (0.05 mL) of compounded semaglutide. The patient injected 50 units (0.5 mL) and went to the emergency room.
FDA says doses beyond the label can mean larger doses, more frequent doses, or faster step-ups. As of May 31, 2026, FDA had received more than 730 adverse event reports of all kinds linked to compounded tirzepatide. FDA says these are likely underreported and that it cannot always tell whether the drug caused the event.
In the FDA Adverse Event Reporting System (FAERS), 29,668 of 160,201 reports naming tirzepatide as the main suspect list "incorrect dose administered." No term was reported more often, in data through July 30, 2026. We queried openFDA on October 5, 2026.
FAERS reports are voluntary and unverified. A report does not prove tirzepatide caused the problem, and these reports do not say why the wrong dose was given.
Because the number of people taking tirzepatide is unknown, FAERS counts cannot show how often dosing errors happen. Reports can include both brand-name and compounded products.
Is there a semaglutide to tirzepatide dose conversion?
There is no official semaglutide to tirzepatide dose conversion: the Zepbound® and Mounjaro® labels give no switching instructions or dose equivalents, as of their August 2026 revisions. The Zepbound® label says not to use it with another tirzepatide product or a GLP-1 medicine. A switch means stopping one and starting the other on your prescriber's plan.
The Zepbound® and Mounjaro® labels list 2.5 mg as the starting dose for everyone, with no exception for people switching from semaglutide.
In a small 2025 records study in Endocrinology and Metabolism, 15 Japanese adults with type 2 diabetes switched from semaglutide 1 mg, all starting tirzepatide at 2.5 mg. Over 3 months, A1C fell by 0.7 points in the 5 people raised to 10 mg, with no significant change in the 10 raised to 7.5 mg.
The authors said early escalation to 10 mg "may be beneficial," though the two groups did not differ significantly.
A prescriber can switch you from Ozempic® (semaglutide) to Mounjaro® for type 2 diabetes, starting at 2.5 mg, since no conversion chart exists.
Semaglutide and tirzepatide dose ladders (not equivalent doses)
| Label detail | Wegovy® (semaglutide) injection | Ozempic® (semaglutide) | Zepbound® and Mounjaro® (tirzepatide) |
|---|---|---|---|
| Starting dose | 0.25 mg weekly for 4 weeks | 0.25 mg weekly for 4 weeks | 2.5 mg weekly (Zepbound®: for 4 weeks) |
| Step-ups | 0.5, 1 and 1.7 mg, 4 weeks each | 0.5 mg, then 1 mg and 2 mg after at least 4 weeks each | 2.5 mg steps after at least 4 weeks each (Mounjaro®: only if more blood sugar control is needed) |
| Maintenance doses | 1.7 or 2.4 mg (2.4 mg recommended) for weight | 0.5, 1 or 2 mg | Zepbound®: 5, 10 or 15 mg (sleep apnea: 10 or 15 mg); Mounjaro®: not named |
| Maximum weekly dose | 7.2 mg for weight, after at least 4 weeks on 2.4 mg | 2 mg | 15 mg (adults) |
| Label revision | June 2026 | May 2026 | August 2026 |
Rows show each label's own schedule. Doses on the same row are not equivalent. Sources: Wegovy®, Ozempic®, Zepbound® and Mounjaro® Prescribing Information.
For results and side effects side by side, see Zepbound® vs. Wegovy®: results, side effects and dosing.
Who should not take tirzepatide, and what should you check before each dose increase?
Per the Zepbound® and Mounjaro® labels, tirzepatide is not for people with a personal or family history of MTC or MEN 2, or a serious allergy to it. Before each increase, check birth control, diabetes medicines and ongoing stomach side effects with your prescriber.
Do not take (contraindications): a personal or family history of MTC or MEN 2, or a known serious allergic reaction to tirzepatide or any of its ingredients.
Not recommended or not studied:
- Children: the Zepbound® label says it is not known if Zepbound® is safe and effective in children.
- Similar medicines: the Zepbound® label advises against using it with another tirzepatide product or a GLP-1 medicine.
- Severe gastroparesis (very slow stomach emptying): the Zepbound® label does not recommend tirzepatide for people with this condition.
- Pregnancy: tirzepatide may harm an unborn baby, so the Zepbound® label says to stop it when pregnancy is recognized. Tell your provider if you become pregnant.
Before you start tirzepatide and before each dose increase, tell your prescriber if you:
- Take birth control pills: the labels advise a non-oral method, or an added barrier method, for 4 weeks after starting and after each dose increase.
- Take insulin or a sulfonylurea: the dose of those medicines may need to be lowered to reduce the risk of low blood sugar.
- Still have nausea, vomiting or diarrhea from the last step: fluid loss from these side effects can lead to dehydration and kidney problems.
- Have type 2 diabetes and a history of diabetic retinopathy: this means eye damage from diabetes.
- Have surgery or a procedure with anesthesia or deep sedation planned: tirzepatide may raise the chance of food getting into the lungs, per the Zepbound® Medication Guide.
Tirzepatide can make birth control pills work less well because it slows stomach emptying, per the Zepbound® and Mounjaro® labels.
When should you see a healthcare provider about your tirzepatide dose?
Call your prescriber about your tirzepatide dose if stomach side effects do not go away, you cannot keep fluids down, or you notice gallbladder or low blood sugar signs. Contact your provider if you have any of these:
- Stomach problems that are severe or will not go away.
- Nausea, vomiting or diarrhea that does not go away, which can lead to dehydration.
- Gallbladder signs: pain in the upper stomach, fever, yellow skin or eyes, or clay-colored stools.
- A lump or swelling in the neck, trouble swallowing, shortness of breath, or hoarseness that will not go away.
- Changes in vision, if you have type 2 diabetes.
- Side effects that make you want to skip or delay your next step-up.
- Several weeks of missed doses, before you restart.
Call 911 or go to the nearest ER if you have any of these signs while taking tirzepatide:
- Signs of a severe allergic reaction: swelling of the face, lips, tongue or throat, or problems breathing or swallowing. Other signs are a severe rash or itching, fainting or dizziness, or a very rapid heartbeat. Stop tirzepatide.
- Severe stomach pain that will not go away, with or without vomiting, sometimes felt in your back. Pain like this can be a sign of pancreatitis (inflammation of the pancreas). Stop tirzepatide.
- Signs of very low blood sugar that do not improve, such as confusion, slurred speech, shakiness or drowsiness.
- Taking far too much tirzepatide: call the Poison Help line at 1-800-222-1222 or go to the nearest ER right away.
The warning signs above come from the Zepbound® Medication Guide, revised August 2026.
Bottom line
- Tirzepatide comes in six weekly doses, from 2.5 to 15 mg. Both brands step up 2.5 mg at a time after at least 4 weeks; Mounjaro® steps only if more blood sugar control is needed.
- Zepbound® maintenance doses are 5, 10 or 15 mg for weight and 10 or 15 mg for sleep apnea; 15 mg is the adult maximum.
- Tirzepatide stomach side effects happen mostly during dose increases, and the prescriber can hold a step or choose a lower maintenance dose.
- Units measure liquid, not drug: a Zepbound® or Mounjaro® single-dose vial dose is 50 units, and any other vial depends on the mg/mL on its label.
Frequently asked questions
What dose of Zepbound® is most effective?
Zepbound® 15 mg had the largest average weight loss in SURMOUNT-1, the main weight trial of 2,539 adults: 20.9% over 72 weeks. The 10 mg and 5 mg groups lost 19.5% and 15.0%, vs 3.1% on placebo, but the trial did not compare doses with each other. The label says to weigh response and tolerability when choosing a dose.
How many units is 2.5 mg of tirzepatide?
Tirzepatide 2.5 mg is 50 units on a U-100 syringe when the concentration is 5 mg/mL, as in a Zepbound® or Mounjaro® 2.5 mg single-dose vial. At 10 mg/mL it is 25 units, and at 25 mg/mL it is 10 units. Read the mg/mL on your own label, and follow your prescriber's and pharmacy's instructions.
What is the starting dose of compounded tirzepatide?
Compounded tirzepatide has no FDA-approved starting dose, because it is not FDA-approved and is not a generic of Zepbound® or Mounjaro®, so the prescriber sets the dose. Zepbound® and Mounjaro® start at 2.5 mg once a week, per their labels, and the trial results come from those brands. Units depend on the pharmacy's mg/mL.
What should I expect after my first dose of Zepbound®?
After a first Zepbound® dose, nausea, diarrhea or vomiting can happen; the label says most occur during dose increases and fade over time. It slows stomach emptying most after the first dose, which can make birth control pills work less well. The label advises a backup or non-oral method for 4 weeks after starting and after each dose increase.
What is the highest dose of Mounjaro®?
The highest dose of Mounjaro® is 15 mg once a week for adults, per its August 2026 label. For children 10 and older with type 2 diabetes, the highest dose is 10 mg once a week. Adults can reach 15 mg at week 21 at the earliest, and each step happens only if more blood sugar control is needed.
Is 2.5 mg of tirzepatide enough to lose weight?
No, 2.5 mg of tirzepatide is a starting dose: the Zepbound® label says it is for starting treatment and is not approved as a maintenance dose. The SURMOUNT-1 trial tested 5, 10 and 15 mg, so the label's weight results include no 2.5 mg group.
Do higher tirzepatide doses cost more?
Not always: what you pay for a tirzepatide dose depends on the form, your insurance plan and your pharmacy. Insurance may not cover every tirzepatide dose or form the same way, so ask your pharmacist before each step-up. Our Zepbound® and Mounjaro® cost and coverage guide explains what affects what you pay.
peptides.io relies on primary sources: FDA labels and safety communications, peer-reviewed trials, and federal health agencies. Read our editorial policy.
Sources
- 1. Eli Lilly and Company. (2025). A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1) (ClinicalTrials.gov Identifier NCT04184622; last updated July 24, 2025) [Clinical trial registration and results]. ClinicalTrials.gov, U.S. National Library of Medicine. Retrieved October 5, 2026, from https://clinicaltrials.gov/study/NCT04184622
- 2. Eli Lilly and Company. (2026a). Mounjaro® (tirzepatide) injection, for subcutaneous use: Prescribing information (Revised 08/2026; SPL version 40) [Drug label]. DailyMed, U.S. National Library of Medicine. Retrieved October 5, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- 3. Eli Lilly and Company. (2026b). Zepbound® (tirzepatide) injection, for subcutaneous use: Prescribing information and Medication Guide (Revised 08/2026; SPL version 40) [Drug label]. DailyMed, U.S. National Library of Medicine. Retrieved October 5, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 4. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K., & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519
- 5. Frías, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., & Haupt, A. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet, 392(10160), 2180-2193. https://doi.org/10.1016/S0140-6736(18)32260-8
- 6. Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145
- 7. Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., le Roux, C. W., Srinath, R., Gomez-Valderas, E., Arad, A. D., Das, S., Dunn, J. P., Ribeiro, A., Glass, L. C., & Lee, C. J. (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): A multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 407(10545), 2305-2318. https://doi.org/10.1016/S0140-6736(26)00656-2
- 8. Institute for Safe Medication Practices. (2024, March 7). Accidental overdoses and adverse effects from compounded GLP-1 agonists. ISMP Medication Safety Alert! Acute Care, 29(5). Retrieved October 5, 2026, from https://www.ismp.org/sites/default/files/newsletter-issues/20240307.pdf
- 9. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
- 10. Kurinami, N., Takada, M., Sugiyama, S., Yoshida, A., Hieshima, K., Suzuki, T., Miyamoto, F., Kajiwara, K., Jinnouchi, K., Ashida, K., Nomura, M., & Jinnouchi, H. (2025). Early dose escalation of tirzepatide after switching from semaglutide in type 2 diabetes mellitus. Endocrinology and Metabolism, 40(6), 1012-1015. https://doi.org/10.3803/EnM.2025.2420
- 11. Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., Bednarik, J., & SURMOUNT-OSA Investigators. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193-1205. https://doi.org/10.1056/NEJMoa2404881
- 12. MedlinePlus. (2024). Giving an insulin injection. U.S. National Library of Medicine. Retrieved October 5, 2026, from https://medlineplus.gov/ency/patientinstructions/000660.htm
- 13. Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition, 122(1), 344-367. https://doi.org/10.1016/j.ajcnut.2025.04.023
- 14. Novo Nordisk. (2026a). Ozempic® (semaglutide) injection, for subcutaneous use: Prescribing information (Revised 05/2026). Retrieved October 5, 2026, from https://www.novo-pi.com/ozempic.pdf
- 15. Novo Nordisk. (2026b). Wegovy® (semaglutide) injection, for subcutaneous use; Wegovy® (semaglutide) tablets, for oral use: Prescribing information (Revised 06/2026). Retrieved October 5, 2026, from https://www.novo-pi.com/wegovy.pdf
- 16. U.S. Food and Drug Administration. (2024, July 26). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Retrieved October 5, 2026, from https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- 17. U.S. Food and Drug Administration. (2026a, April 1). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Retrieved October 5, 2026, from https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- 18. U.S. Food and Drug Administration. (2026b, October 1). FDA's concerns with unapproved GLP-1 drugs used for weight loss. Retrieved October 5, 2026, from https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- 19. U.S. Food and Drug Administration. (2026c). openFDA drug adverse event endpoint: Reports with tirzepatide as the primary suspect drug (FAERS data through July 30, 2026) [Data set]. Retrieved October 5, 2026, from https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:"TIRZEPATIDE"+AND+patient.drug.drugcharacterization:1&count=patient.reaction.reactionmeddrapt.exact
- 20. U.S. Food and Drug Administration. (2026d). openFDA Drugs@FDA endpoint: Tirzepatide applications, NDA 217806 (Zepbound®) and NDA 215866 (Mounjaro®), approval history [Data set]. Retrieved October 5, 2026, from https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:"TIRZEPATIDE"
Comments